Definium Therapeutics (DFTX) announced Monday that its synthetic LSD successfully eased anxiety symptoms in patients, with a 9.8-point improvement on the Hamilton Anxiety Rating Scale after 12 weeks, compared to 4.7 points in the placebo group. The effect was rapid, showing responses as early as the initial stages of treatment. The company's shares, already up 190% this year, saw another surge following the announcement.